DNLI vs IONS
DNLI: Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the blood-brain barrier for the treatment of neurodegenerative diseases and rare disorders. IONS: Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic diseases, now executing independent U.S. launches while generating royalty revenue from major pharma partnerships.
Side-by-side fundamentals
| Metric | DNLI | IONS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $23.64 | $54.01 | |
| Market cap as of 2026-07-23 | $3.7B | $8.8B | |
| PEG as of 2026-07-23 | -1.05 | n/a | |
| Net margin as of 2026-07-23 | -36.5% | -30.9% | IONS higher |
| Gross margin as of 2026-07-23 | n/a | +98.3% | |
| Operating margin as of 2026-07-23 | -49.7% | -33.3% | IONS higher |
| ROE as of 2026-07-23 | -50.1% | -58.7% | DNLI higher |
| ROA as of 2026-07-23 | -44.2% | -10.1% | IONS higher |
| Debt / equity as of 2026-07-23 | 0.01 | 4.76 | DNLI lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +47.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +17.1% | |
| Beta as of 2026-07-23 | 0.99 | 0.38 | |
| 1-year return as of 2026-07-22 close | +72.3% | +28.5% | DNLI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.